Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Cutaneous Lupus Erythematosus
- Disease Description and Etiology
- Prevalence
- Connection Between Cutaneous LE and Systemic LE
- Overview of Current Drug Therapies
- Corticosteroids
- Antimalarials
- Calcineurin Inhibitors
- Anti-Leprosy Agents
- Retinoids
- Systemic Lupus Erythematosus
- Disease Symptoms and Etiology
- Prevalence
- Overview of Current Drug Therapies
- Nonsteroidal Anti-Inflammatory Agents
- Corticosteroids
- Immunosuppressive/Immunomodulatory Agents
- Emerging Therapies for the Treatment of Cutaneous Lupus Erythematosus
- Genentech' s Efalizumab
- Astion Pharma' s ASF-1096
- Emerging Therapies for the Treatment of Systemic Lupus Erythematosus
- Immunomodulators
- Aspreva/Roche' s Mycophenolate Mofetil
- Wyeth' s Sirolimus
- Astellas' s Tacrolimus
- Biological Agents
- Genentech/Biogen Idec' s Rituximab
- UCB/Immunomedics' Epratuzumab
- Human Genome Science/GlaxoSmithKline' s Belimumab
- Bristol-Myers Squibb' s Abatacept
- Teva' s Edratide
- Other Approaches
- Genelabs Technologies' Prasterone
- La Jolla Pharmaceutical' s Abetimus Sodium
- Outlook
Tables
- 1. Current Therapies for the Treatment of Cutaneous Lupus Erythematosus
- 2. American College of Rheumatology Criteria for Classification of
Systemic Lupus Erythematosus
- 3. Prevalent Cases of Systemic Lupus Erythematosus in the Three
Major-Market Regions by Gender, 2005
- 4. Current Therapies for the Treatment of Systemic Lupus Erythematosus
- 5. Emerging Therapies for the Treatment of Cutaneous Lupus Erythematosus
- 6. Emerging Therapies for the Treatment of Systemic Lupus Erythematosus
Figures
- 1. Onset and Complications of Systemic Lupus Erythematosus
- 2. Immunopathological Targets of Emerging Biological Therapies for
Systemic Lupus Erythematosus
- 3. Emerging Agents for SLE Approved or In Development for Other Indications
|
Related Report
|
View Cart
